Liang Cheng, Director of Anatomic Pathology and Director of Molecular Pathology at Lifespan Academic Medical Center, Vice Chair for Translational Research at the Warren Alpert Medical School of Brown University and President at International Society of Urological Pathology, shared a post on X:
“What’s new in the space of antibody-drug conjugates (ADCs) for metastatic castration-resistant prostate cancer (mCRPC)? Congratulations to Benedito A. Carneiro, Claire, and colleagues Wafik S. El-Deiry, for publishing this outstanding state-of-the-art review in NPJ Precision Oncology
PMID:41238753 ADCs represent a rapidly evolving class of biotherapeutics, combining the tumor-targeting specificity of monoclonal antibodies with the cytotoxic potency of small-molecule payloads.
This comprehensive review outlines advances in cytotoxic payload and linker chemistry, and synthesizes emerging evidence on membrane antigens overexpressed in prostate cancer – including PSMA, B7-H3, STEAP1, TROP2, CD46, TF, DLL3, SLC44A4, HER2/HER3, Nectin-4, 5T4, KAAG1, ASCT2, LYPD3, Tag-72, TM4SF1, CDH3, ROR1, and PSCA. Although no ADC has yet been approved for prostate cancer due to challenges related to safety, specificity, and therapeutic window, progress in antigen selection, linker design, and next-generation payloads is accelerating development.
These innovations hold significant promise to reshape the treatment paradigm for mCRPC and improve patient outcomes.”
Title: The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Authors: Claire Lin, Matthew Hadfield, Ariana Santopietro, Galina Lagos, Liang Cheng, Wafik El-Deiry, Rahul Aggarwal, Anthony Mega, Elias Hyams, Benedito Carneiro
Read the Full Article.
More posts featuring Liang Cheng.
